The 3P Laboratory (Pharmacokinetics (PK), Pharmacodynamics (PD) and Pharmacogenetics (PG)) was established by the UWCCC more than 25 years ago to support the translational and clinical research activities of our members. The mission of the 3P Laboratory is to advance cancer research by providing expertise;leadership;and bioanalytical assay development, validation and performance in support of the clinical, translational and laboratory research endeavors of UWCCC investigators. The 3P Lab provides UWCCC members with sample acquisition, processing, storage and shipping services for all PK/PD/PG clinical studies. It provides analysis of samples for PK/PD/PG studies in support of multiple NCI grants as well as research conducted by individual UWCCC investigators. In addition, the 3P Lab provides services for investigators in the preclinical setting to support new drug development. Services include generation of tumor xenografts for testing of investigational compounds, as well as evaluating plasma and intra-tumor drug levels in animal models. This service includes development and performance of original assays for new agents;assays to monitor endogenous biochemicals;and genotyping and mutation assays. Finally, the 3P Lab offers access to their bioanalytical instrumentation to trained UWCCC investigators.

Public Health Relevance

The 3P Laboratory (Pharmacokinetics, Pharmacodynamics and Pharmacogenetics) provides analytical support for biospecimens obtained in the clinical trials conducted at the University of Wisconsin Carbone Cancer Center.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA014520-40
Application #
8762764
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2014-04-01
Budget End
2015-03-31
Support Year
40
Fiscal Year
2014
Total Cost
$125,938
Indirect Cost
$59,444
Name
University of Wisconsin Madison
Department
Type
DUNS #
161202122
City
Madison
State
WI
Country
United States
Zip Code
53715
Robins, H Ian; Nguyen, HuyTram N; Field, Aaron et al. (2018) Molecular Evolution of a Glioblastoma Controlled With Tumor Treating Fields and Concomitant Temozolomide. Front Oncol 8:451
Esbona, Karla; Yi, Yanyao; Saha, Sandeep et al. (2018) The Presence of Cyclooxygenase 2, Tumor-Associated Macrophages, and Collagen Alignment as Prognostic Markers for Invasive Breast Carcinoma Patients. Am J Pathol 188:559-573
Hernández-Santos, Nydiaris; Wiesner, Darin L; Fites, J Scott et al. (2018) Lung Epithelial Cells Coordinate Innate Lymphocytes and Immunity against Pulmonary Fungal Infection. Cell Host Microbe 23:511-522.e5
van Ravesteyn, Nicolien T; van den Broek, Jeroen J; Li, Xiaoxue et al. (2018) Modeling Ductal Carcinoma In Situ (DCIS): An Overview of CISNET Model Approaches. Med Decis Making 38:126S-139S
Hardin, Heather; Helein, Holly; Meyer, Kristy et al. (2018) Thyroid cancer stem-like cell exosomes: regulation of EMT via transfer of lncRNAs. Lab Invest 98:1133-1142
Pezzi, Hannah M; Niles, David J; Schehr, Jennifer L et al. (2018) Integration of Magnetic Bead-Based Cell Selection into Complex Isolations. ACS Omega 3:3908-3917
Alagoz, Oguzhan; Ergun, Mehmet Ali; Cevik, Mucahit et al. (2018) The University of Wisconsin Breast Cancer Epidemiology Simulation Model: An Update. Med Decis Making 38:99S-111S
Lyu, Zhigang; Kang, Lei; Buuh, Zakey Yusuf et al. (2018) A Switchable Site-Specific Antibody Conjugate. ACS Chem Biol 13:958-964
Romero-Masters, James C; Ohashi, Makoto; Djavadian, Reza et al. (2018) An EBNA3C-deleted Epstein-Barr virus (EBV) mutant causes B-cell lymphomas with delayed onset in a cord blood-humanized mouse model. PLoS Pathog 14:e1007221
Xu, Cheng; Chen, Feng; Valdovinos, Hector F et al. (2018) Bacteria-like mesoporous silica-coated gold nanorods for positron emission tomography and photoacoustic imaging-guided chemo-photothermal combined therapy. Biomaterials 165:56-65

Showing the most recent 10 out of 1528 publications